Results 1 to 10 of about 44,611 (218)

Leishmaniasis, Cutaneous

2015
openaire   +1 more source

Leishmaniasis, cutaneous

2004
openaire   +1 more source

[Cutaneous leishmaniasis].

Bulletin de la Societe francaise de dermatologie et de syphiligraphie, 1970
openaire   +1 more source

Cutaneous Leishmaniasis in High‐Altitude: A Case Report From Nepal [PDF]

Clinical Case Reports
Leishmaniasis is a parasitic infection caused by Leishmania and spread by the bite of a sandfly, most commonly Phlebotomus. Among the three subtypes of Leishmaniasis, cutaneous leishmaniasis is the most common form.
Eliz Aryal, Rohan Sapkota, Sunny Shrestha, Arika Baral, Santosh Sapkota, Mandish Prasad Phuyal   +5 more
doaj   +3 more sources

A 10-year registry-based retrospective study of cutaneous Leishmaniasis in Mashhad, northeastern Iran: Demographic, clinical, and therapeutic profiles of 1537 cases [PDF]

Parasite Epidemiology and Control
Background: Cutaneous leishmaniasis (CL) remains one of the most prevalent neglected tropical diseases, imposing a substantial health burden in many developing countries.
Vahid Mashayekhi-Goyonlo, Pouran Layegh, Zahra Ghasemi, Masomeh Hosseini-Nezhad, Ali Tajik   +4 more
doaj   +2 more sources

Spiny Hyperkeratosis-Like Follicular Mycosis Fungoides: A Case Report [PDF]

Middle East Journal of Cancer, 2023
Folliculotropic mycosis fungoides (FMF) is a rare variant of cutaneous T-cell lymphoma which is categorized as a separate entity. In histopathology, malignant lymphocytes selectively surround and infiltrate hair follicles.
Shatila Torabi, Sara Fakhraei, Naser Tayebi Meibodi, Farnaz Ahmadpour   +3 more
doaj   +1 more source

Evaluation of clinical risk factors for systemic antimony treatment failure in patients with acute cutaneous leishmaniasis referred to dermatology clinics of Mashhad University of Medical Sciences, Iran [PDF]

Journal of Kerman University of Medical Sciences, 2023
Background: Systemic or topical form of pentavalent antimony compounds such as Meglumine Antimoniate (MA) are used as Standard treatment for cutaneous leishmaniasis (CL).
Yalda Nahidi, Vahid Mashayekhi Goyonlo, Malihe Dadgarmoghaddam, Maesumeh Hosseininejad, Tahmineh Malakifard, Yasaman Rastgar   +5 more
doaj   +1 more source

Brain Involvement in Leishmaniasis. [PDF]

Cell Biochem Funct
ABSTRACT Leishmaniasis is a neglected tropical disease caused by infection with the protozoan parasite Leishmania and it is a significant global health problem. The disease has a wide clinical spectrum, from tegumentary leishmaniasis (TL) that encompasses cutaneous (CL), mucosal (ML) and cutaneous‐diffuse (CDL) forms, to the potentially fatal systemic ...
Freitas CS, Coelho EAF, Christodoulides M.   +2 more
europepmc   +2 more sources

Auricular Sebaceous Carcinoma, Report of a Rare Case [PDF]

Middle East Journal of Cancer, 2023
Sebaceous carcinoma is a rare and invasive tumor that originates from the Zeis and Meibomian glands around the eyes as well as in sebaceous glands in other head and neck areas and less commonly on the trunk.
Shatila Torabi, Syed Mohammad Naqvi, Fereshteh Zamiri   +2 more
doaj   +1 more source

Translational Pharmacokinetic-Pharmacodynamic Modeling and Efficacious Human Dose Prediction of DNDI-6148 for the Treatment of Cutaneous Leishmaniasis. [PDF]

Clin Transl Sci
ABSTRACT Cutaneous leishmaniasis is a neglected tropical disease with only one oral treatment option. DNDI‐6148 is an orally bioavailable compound with potent antiparasitic activity in preclinical studies. Establishing skin target‐site pharmacokinetic/pharmacodynamic (PK/PD) relationships is essential to enable its clinical development.
Henninger RH, Schouten WM, Arana B, Gillon JY, Mowbray CE, Kratz JM, Van Bocxlaer K, Dorlo TPC.   +7 more
europepmc   +2 more sources